L'aspirine en prevention primaire des maladies cardio-vasculaires chez le patient diabetique.

Aspirin/therapeutic use; Cardiovascular Diseases/metabolism/prevention & control; Diabetes Complications/metabolism/prevention & control; Female; Humans; Insulin Resistance; Male; Platelet Aggregation Inhibitors/therapeutic use; Sex Factors

Abstract :

[en] Acetylsalicylic acid (aspirin) is widely used as antiplatelet therapy for the primary and secondary prevention of cardiovascular diseases. However, the effects appear to be different according to the studied population, with a reduction of coronary events in men and, rather, a diminution of strokes in women. Diabetes mellitus markedly increases the risk of cardiovascular diseases, with an especially elevated relative risk among women. We present a detailed analysis of the literature about the efficacy of aspirin in the primary prevention of cardiovascular complications in the diabetic population. Limited available data suggest a lower protection in the diabetic than in the non-diabetic population. A greater aspirin resistance has been suggested in diabetic patents, which might lead to the use of a higher daily dosage of aspirin in diabetic than in non diabetic patients. Whatsoever, aspirin remains the first antiplatelet agent in the diabetic population in all international guidelines of cardiovascular prevention.

Disciplines :

Pharmacy, pharmacology & toxicology
Endocrinology, metabolism & nutrition

Author, co-author :

Legrand, Delphine ; Centre Hospitalier Universitaire de Liège - CHU > Frais communs médecine

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale

Language :

French

Title :

L'aspirine en prevention primaire des maladies cardio-vasculaires chez le patient diabetique.

Alternative titles :

[en] Aspirin for primary prevention of cardiovascular diseases in diabetic patients: focus on gender difference and insulin resistance

Publication date :

2006

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

682-90

Peer reviewed :

Peer reviewed

Additional URL :

http://www.rmlg.ulg.ac.be

Available on ORBi :

since 02 March 2009

Statistics

Number of views

1066 (8 by ULiège)

Number of downloads

1288 (6 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Patrono C, Garcia Rodriguez L, Landolfi R, Baigent C. - Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med, 2005, 353, 2373-2383.
Hermans C, Brohet Ch. - La thérapeutique antiplaquettaire. In : Athérosclérose Athérothrombose (Eds : Kulbertus H., Van Mieghem W.), Transmed Medical Communications, Lubbeek, Belgium, 2006, 212-229.
Antithrombotic Trialists' Collaboration. - Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J, 2002, 324, 71-86.
Kulbertus H. - L'aspirine : acquisitions récentes en pré vention cardiovasculaire. Rev Med Liège, 2004, 59, 695-703.
Scheen AJ, Lefèbvre PJ, Kulbertus H. - Comment je préviens... Les maladies cardio-vasculaires par une approche pharmacologique combinée : y a-t-il place pour une «polypill» ? Rev Med Liège, 2003, 57, 527-533.
Beckman JA, Creager MA, Libby P. - Diabetes and atherosclerosis. Epidemiology, pathophysiology, and management. JAMA, 2002, 287, 2570-2581.
Biondi-Zoccai GG, Abbate A, Liuzzo G, et al. - Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol, 2003, 41, 1071-1077.
Barrett-Connor E, Giardina EG, Gitt AK, et al. - Women and heart disease : the role of diabetes and hyperglycemia. Arch Intern Med, 2004, 164, 934-942.
Scheen AJ. - Le syndrome métabolique : physiopathologie et traitement. In : Athérosclérose Athérothrombose (Eds : Kulbertus H., Van Mieghem W.), Transmed Medical Communications, Lubbeek, Belgium, 2006, 161-190.
American Diabetes Association. - Aspirin therapy in diabetes. Diabetes Care, 2004, 27, S72-73.
Pearson TA, Steven N, Blair SN, et al. - American Heart Association guidelines for primary prevention of cardiovascular disease and stroke. Circulation, 2002, 106, 388-391.
Charbonnel B, Bouhanick B, Le Feuvre C et le Groupe de travail. - Recommandations SFC/ALFEDIAM sur la prise en charge du patient diabétique vu par le cardiologue. Arch Mal Coeur Vaiss, 2004, 97, 229-249.
U.S. Preventive Services Task Force. - Aspirin for the primary prevention of cardiovascular events : recommendation and rationale. Ann Intern Med, 2002, 136, 157-160.
ETDRS Investigators. - Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study Report 14. JAMA, 1992, 268, 1292-1300.
Hansson L, Zanchetti A, Carruthers SG, et al for the HOT Study Group. - Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet, 1998, 351, 1755-1762.
Collaborative Group of the Primary Prevention Project. - Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet, 2001, 357, 89-95.
Ridker PM, Cook NR, Lee IM, et al. - A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med, 2005, 352, 1293-1304.
Peto R, Gray R, Collins R, et al. - Randomised trial of prophylactic dialy aspirin in British male doctors. Br Med J, 1988, 296, 313-316.
Steering Committee of the Physicians' Health Study Research Group. - Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med, 1989, 321, 129-135.
The Medical Research Council's General Practice Research Framework. - Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet, 1998, 351, 233-241.
Eidelman RS, Hebert PR, Weisman SM, Hennekens CH. - An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med, 2003, 163, 2006-2010.
Berger JS, Roncaglioni MC, Avanzini F, et al. - Aspirin for the primary prevention of cardiovascular events in women and men. A sex-specific meta-analysis of randomized controlled trials. JAMA, 2006, 295, 306-313.
Levin RJ. - The puzzle of aspirin and sex. N Engl J Med, 2005, 352, 1366-1368.
Sacco M, Pellegrini F, Roncaglioni MC, et al. - Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients. Diabetes Care, 2003, 26, 3264-3272.
Krein SL, Vijan S, Pogach LM, et al. - Aspirin use and counselling about aspirin among patients with diabetes. Diabetes Care, 2002, 25, 965-970.
Persell SD, Baker DW. - Aspirin use among adults with diabetes. Recent trends and emerging sex disparities. Arch Intern Med, 2004, 164, 2492-2499.
Wexler DJ, Grant RW, Meigs JB, et al. - Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care, 2005, 28, 514-520.
Vinik AI, Erbas T, Park TS, et al. - Platelet dysfunction in type-2 diabetes. Diabetes Care, 2001, 24, 1476-1485.
Colwell JA, Nesto RW. - The platelet in diabetes. Focus on prevention of ischemic events. Diabetes Care, 2003, 26, 2181-2188.
Nowak SN, Jaber LA. - Aspirin dose for prevention of cardiovascular disease in diabetics. Ann Pharmacother, 2003, 37, 116-121.
Evangelista V, Totani L, Rotondo S, et al. - Prevention of cardiovascular disease in type-2 diabetes : How to improve the clinical efficacy of aspirin. Thromb Haemost, 2005, 93, 8-16.
Patrono C. - Insulin resistance : definition, mechanisms and clinical read-outs. J Thromb Haemost, 2003, 1, 1710-1713.
Hanjis C, Frishman WH, Lerner RG. - Aspirin resistance : mechanisms and clinical implications. Cardiol Rev, 2006, 14, 18-25.
Mehta SS, Silver RJ, Aaronson A, et al. - Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus. Am J Cardiol, 2006, 97, 567-570.
Watala C, Pluta J, Golanski J, et al. - Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med, 2005, 83, 148-158.
Watala C, Boncler M, Gresner P. - Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus. Pharmacol Rep, 2005, 57, 42-58.
Abaci A, Yilmaz Y, Caliskan M, et al. - Effect of increasing doses of aspirin on platelet function as measured by PFA-100 in patients with diabetes. Thromb Res, 2005, 116, 465-470.
Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. - Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes, 2005, 54, 2430-2435.
Bhatt DL, Fox KAA, Hacke W, et al. - Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med, 2006, 354, 1706-1717.
De La Cruz JP, Arrebola MM, Villalobos MA, et al. - Influence of glucose concentration on the effects of aspirin, ticlopidine and clopidogrel on platelet function and platelet-subendothelium interaction. Eur J Pharmacol, 2004, 484, 19-27.
Watala C, Golanski J, Pluta J, et al. - Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin) - its relation to metabolic control. Thromb Res, 2004, 113, 101-113.
Patrono C, Bachmann F, Baigent C, et al. - Expert consensus document on the use of antiplatelet agents. Eur Heart J, 2004, 25, 166-181.
Hennekens CH, Knatterud GL, Pfeffer MA. - Use of aspirin to reduce risks of cardiovascular disease in patients with diabetes. Clinical and research challenges. Diabetes Care, 2004, 27, 2752-2754.
Legrand DA, Scheen AJ - Aspirine et complications microangiopathiques du diabète. Rev Med Liège, 2006, 61, en préparation.